ライフサイエンスコーパス: AVF

1 AVF blood flow rate at 1 day is usually more than 50% of

2 AVF correlated between both techniques (rho = 0.94).

3 AVF draining vein diameter and blood flow rate were asse

4 AVF in mice treated with rapamycin had reduced Akt1 and

5 AVF performance was significantly better along the horiz

6 AVF provides the appropriate parameter to account for pa

7 AVF success was defined as dialysis initiation using the

8 AVFs in the OE mice also had smoother blood flow streaml

9 AVFs matured without prior intervention for 56% of the p

10 A total of 1084 accesses (185 AVF, 296 AVG, 603 CVC) were used for a total of 1381 per

11 loss (requiring intervention after achieving AVF maturation), AVF abandonment, and frequency of inter

12 native functional arterial properties affect AVF development.

13 Animals were sacrificed on day 7 after AVF placement for real-time polymerase chain reaction (n

14 d on the outflow vein at 7 and 21 days after AVF creation.

15 Eleven mice died after AVF placement.

16 ctively in 69 patients within 4 months after AVF placement; adequacy for dialysis was known in 54.

17 o significant complications were noted after AVF ligation.

18 iameter at 1 day, 2 weeks, and 6 weeks after AVF placement.

19 When verified against AVF as the reference test, patients with a false-positiv

20 gative group when mfERG was verified against AVF suggests that mfERG may have the ability to detect c

21 t variable specificity when verified against AVF, OCT, FAF, and a combination of tests.

22 An AVF rather than the planned graft was placed in eight (1

23 eral jugular vein was connected to create an AVF, and CorMatrix scaffold was wrapped around the outfl

24 r (during 2004-2012) who subsequently had an AVF (n=295) or AVG (n=105) placed or no arteriovenous ac

25 with a catheter and no prior AVF; all had an AVF created within 6 months of starting hemodialysis and

26 tive policy that avoided AVF placement if an AVF was predicted to be at high risk of failure resulted

27 g with an HC while awaiting maturation of an AVF (adjusted hazard ratio, 0.77; 95% CI, 0.76-0.79; P <

28 s study, our results suggest that placing an AVF >6-9 months predialysis in the elderly may not assoc

29 higher in patients who initially receive an AVF versus an AVG.

30 Patients receiving an AVF had a higher median annual cost (interquartile range

31 atients receiving an AVG, those receiving an AVF had more frequent surgical access procedures per yea

32 es and access costs in patients receiving an AVF versus an AVG.

33 also approximately twice as likely to use an AVF (aOR 2.3; 95% CI 1.2 to 4.6).

34 tems are significantly more likely to use an AVF at initiation of HD than patients with other insuran

35 of a patient beginning hemodialysis using an AVF by 11-fold (odds ratio, 11.42 [95% CI, 10.93-11.93];

36 4.9% of subjects initiated dialysis using an AVF, and 45.1% of subjects used a catheter or graft.

37 40% were using an AVG, and 26% were using an AVF.

38 ere using an AVG, and 85 (14%) were using an AVF.

39 greater odds of initiating dialysis with an AVF (adjusted odds ratio [aOR] 10.3; 95% confidence inte

40 dently associated with initiating HD with an AVF (aOR 1.4; 95% CI 1.2 to 1.5).

41 anic patients initiated hemodialysis with an AVF less frequently despite being younger and having les

42 persistently initiated hemodialysis with an AVF less frequently than white patients (P < .05 for all

43 tients tend to initiate hemodialysis with an AVF less frequently than white patients despite being yo

44 uary 1, 2005, and December 31, 2008, with an AVF placed as the first predialysis access.

45 s in this cohort, first hemodialysis with an AVF ranged from 11.1% to 22.2% depending on the ESRD Net

46 hite patients initiated hemodialysis with an AVF than black patients or Hispanic patients (18.3% vs 1

47 ease, and cancer than white patients with an AVF.

48 e number of patients who initiate HD with an AVF.

49 rouped as follows: sham; sham+CIMP; AVF; and AVF+CIMP (n=6).

50 d histomorphometry of of the bone in cAF and AVF was significantly superior to bone grafts with a hig

51 ading to accelerated neointima formation and AVF failure.

52 ce, diabetes, vascular disease, obesity, and AVF location were not associated with maturation.

53 increases in 6-week AVF blood flow rate and AVF diameter (per absolute 10% difference in FMD: change

54 with greater 6-week AVF blood flow rate and AVF diameter (per absolute 10% difference in NMD: change

55 s (180 women and 422 men, 459 with upper-arm AVF and 143 with forearm AVF) from seven clinical center

56 point of 1120 mL/min (P = .03) for upper arm AVFs.

57 rvention prior to week 2, 70% with upper-arm AVFs (302 of 433) and 77% with forearm AVFs (99 of 128)

58 orearm AVFs (68 of 124) and 83% of upper-arm AVFs (341 of 411) in surviving patients without thrombos

59 9 of 459), and 87% (401 of 459) of upper-arm AVFs and in 40% (58 of 143), 73% (104 of 143), and 77% (

60 Assisted AVF maturation with one, two, three, or four or more pre

61 this cohort of patients undergoing assisted AVF maturation, we observed a positive association betwe

62 o be involved in the conversion of averufin (AVF) to versiconal hemiacetal acetate (VHA), in Aspergil

63 A more selective policy that avoided AVF placement if an AVF was predicted to be at high risk

64 s needed to verify the linkages for baseline AVF as well as the response measures.

65 For baseline AVF, the best evidence was on 2q22.1 and 2q33.2-q36.3 (i

66 the elderly may not associate with a better AVF success rate.

67 initiation using the AVF, with time between AVF placement and dialysis start as our primary variable

68 ing primary radiocephalic or brachiocephalic AVF creation to receive regional anesthesia (brachial pl

69 ortion of positive test results, followed by AVF.

70 tors may impede AVF lumen expansion to cause AVF maturation failure, a significant clinical problem w

71 school performance in children with cerebral AVF and the American Spinal Injury Association impairmen

72 of gene mutations in pediatric cerebrospinal AVFs, and show the predominance of RASA1 over HHT mutati

73 ce were grouped as follows: sham; sham+CIMP; AVF; and AVF+CIMP (n=6).

74 estored the ability of the mutant to convert AVF to VHA and to produce aflatoxins B(1), G(1), B(2), a

75 Three groups were created: AVF (n = 6), conventional arterial flap (cAF, n = 6) and

76 After 7 and 21 days, AVFs or contralateral internal jugular veins were proces

77 h improved long-term patency, enhanced early AVF remodeling and sustained reduction of SMC proliferat

78 trial in patients undergoing upper extremity AVF placement was performed to evaluate the safety and e

79 compared these findings with those in failed AVFs from patients with ESRD.

80 Abdominal visceral fat (AVF), abdominal subcutaneous fat (ASF), and abdominal to

81 echanical profiles associated with favorable AVF remodeling.

82 The loss of attentional visual field (AVF) has been linked to poor mobility and car crashes.

83 ce tomography (OCT), automated visual field (AVF), and angiograms.

84 The attentional visual field (AVF), which describes a person's ability to divide atten

85 when compared with automated visual fields (AVFs), fundus autofluorescence (FAF), and optical cohere

86 Arteriovenous fistula (AVF) access improves survival in patients with end-stage

87 rsistence of a patent arteriovenous fistula (AVF) after transplantation may contribute to ongoing mal

88 ed with the use of an arteriovenous fistula (AVF) at first hemodialysis.

89 d the outflow vein of arteriovenous fistula (AVF) at the time of creation could reduce VNH.

90 ion of a hemodialysis arteriovenous fistula (AVF) causes aberrant vascular mechanics at and near the

91 iameters for surgical arteriovenous fistula (AVF) creation but fails to improve AVF maturation rates.

92 ular mapping prior to arteriovenous fistula (AVF) creation for hemodialysis but cannot demonstrate th

93 irst occurrence of an arteriovenous fistula (AVF) in a transplanted allograft bundle (3).

94 dialysis (HD) with an arteriovenous fistula (AVF) in countries with universal health care systems com

95 Arteriovenous fistula (AVF) is the preferred type of vascular access for hemodi

96 Arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis (

97 Arteriovenous fistula (AVF) maturation failure is the primary cause of dialysis

98 f death, high rate of arteriovenous fistula (AVF) maturation failure, and poor vascular access outcom

99 Low rates of arteriovenous fistula (AVF) maturation prevent optimal fistula use for hemodial

100 hemodialysis (HD) via arteriovenous fistula (AVF) or arteriovenous graft (AVG) vs hemodialysis cathet

101 go placement of a new arteriovenous fistula (AVF) or arteriovenous graft (AVG).

102 rtant determinants of arteriovenous fistula (AVF) success.

103 ncident and prevalent arteriovenous fistula (AVF) use among patients with ESRD.

104 Arteriovenous fistula (AVF) was created in C57BL/J6 mice, and CIMP was administ

105 through an autologous arteriovenous fistula (AVF), 49% through a prosthetic graft (AVG), and 23% thro

106 rebral or spinal pial arteriovenous fistula (AVF), and to describe their clinical characteristics.

107 Arteriovenous fistulae (AVF) are the most common access created for hemodialysis

108 Arteriovenous fistulae (AVF) have advantages over arteriovenous grafts (AVG) and

109 1 year were 16% for arteriovenous fistulas (AVFs) and 23% for polytetrafluoroethylene (PTFE) grafts.

110 About half of arteriovenous fistulas (AVFs) require one or more interventions before successfu

111 he failure of 60% of arteriovenous fistulas (AVFs) within 2 years.

112 m blood flow through arteriovenous fistulas (AVFs).

113 In arterialized venous flaps (AVFs) the venous network is used to revascularize the fl

114 egulating local vascular mechanics following AVF creation.

115 Annual mortality rates were 11.7% for AVF, 14.2% for AVG, and 16.1% for CVC.

116 After adjusting for AVF area, we found that poorer cognitive and vision perf

117 After controlling for AVF location, preoperative ultrasound measurements, and

118 On the basis of accepted standards for AVF creation, an algorithm was developed to predict AVF

119 To assess the optimal time for AVF placement in the elderly, we linked data from the US

120 arterial sections examined as unsuitable for AVF creation compared with 61 of 236 (26%) sections with

121 d only patients who had suitable vessels for AVF creation were enrolled (n = 162).

122 ar primary assisted patency rates of 67% for AVFs and 68% for PTFE grafts.

123 -9 months predialysis compared with 0.72 for AVFs created >12 months predialysis (P<0.001).

124 , with a mean of 0.64 procedures/patient for AVFs created 6-9 months predialysis compared with 0.72 f

125 459 with upper-arm AVF and 143 with forearm AVF) from seven clinical centers underwent preoperative

126 In 55% of forearm AVFs (68 of 124) and 83% of upper-arm AVFs (341 of 411)

127 104 of 143), and 77% (110 of 143) of forearm AVFs at 1 day, 2 weeks, and 6 weeks, respectively.

128 r-arm AVFs (302 of 433) and 77% with forearm AVFs (99 of 128) maintained at least 85% of their week 2

129 The air volume fraction (AVF) was estimated from relative signal intensity (aorti

130 t fraction (i.e., adipocyte volume fraction [AVF]) and not chemical fat fraction, because fat fractio

131 increase in MMP activity in the hearts from AVF mice compared with sham, and treatment with CIMP dec

132 The success rate increased as time from AVF creation to HD initiation increased from 1-3 months

133 icantly improved both primary and functional AVF patency at 1 year and is cost-effective.

134 s failure to achieve a clinically functional AVF within 8 weeks.

135 tients initiated dialysis with a functioning AVF or AVG; 46.8% of AVFs were created <90 days before d

136 idelines in 1997 recommending 50% or greater AVF rates in incident HD patients.

137 enrolled, of whom 40 (mean age 59 years) had AVF creation and completed both scans.

138 ia (VNH) at the outflow vein of hemodialysis AVF is a major factor contributing to failure.

139 ntional procedures performed on hemodialysis AVFs and AVGs is relatively low.

140 To identify how AVFs fail, we anastomosed the carotid artery to the inte

141 d both M1- and M2-type macrophages; however, AVF patency was reduced.

142 In human AVF and a mouse aortocaval fistula model, Eph-B4 protein

143 milarly, ETS-1 expression increased in human AVFs compared with normal veins.

144 these aberrant mechanical factors may impede AVF lumen expansion to cause AVF maturation failure, a s

145 within a year, suggesting a need to improve AVF maturation and patency.

146 fistula (AVF) creation but fails to improve AVF maturation rates.

147 RC1 axis alters venous remodeling to improve AVF patency.

148 potential translational strategy to improve AVF patency.

149 identity; increased Eph-B activity improves AVF patency.

150 hese results suggest that rapamycin improves AVF patency by reducing early inflammation and wall thic

151 d mesenchymal stem cells (MSCs) in improving AVF function.

152 In AVF mice, the cardiac pressure-length relationship was s

153 e calculated the 30-month slope of change in AVF prevalence from monthly facility reports collected b

154 The overall change in AVF was -0.34 degrees (SD = 4.32), which was a significa

155 eased plasma and LV tissue levels of CIMP in AVF mice; there was no increase in sham animals.

156 e risk factors associated with a decrease in AVF over time among participants in the Salisbury Eye Ev

157 were increased in AVF mice and decreased in AVF mice treated with CIMP.

158 Compared with sham, CIMP was decreased in AVF mice, and CIMP protein transfer increased plasma and

159 the standard deviation for the difference in AVF over 2 years of 4.3 degrees , two subgroups were cre

160 TS-1 as a mediator of neointima formation in AVF and may result in the development of novel strategie

161 ESRD but not with subsequent improvement in AVF use among prevalent patients.

162 arker of oxidative stress, were increased in AVF mice and decreased in AVF mice treated with CIMP.

163 Akt1 expression also increased in AVF; Akt1 knockout mice showed reduced fistula diameter

164 Loss in AVF over time is related independently to decrements in

165 le of ETS-1 in the formation of neointima in AVF.

166 e macrophages may play a mechanistic role in AVF maturation.

167 In AVFs, ETS-1 mRNA increased 2.5-fold at 7 days and 4-fold

168 to bone grafts with a higher bone volume in AVFs (p = 0.01).

169 k Programs in the United States and incident AVF frequency.

170 ounty-level poverty and ascertained incident AVF use from the Medicare CMS 2728 form.

171 to compare patient characteristics, incident AVF frequencies, and corrected mortality hazards between

172 Current incident AVF practice falls exceedingly short years after recomme

173 ula First Catheter Last) target for incident AVF access.

174 ed regional variation in functional incident AVF frequency and risk-adjusted ESRD mortality exists ac

175 y poverty inversely associated with incident AVF use (P for trend = 0.001).

176 reatment is located associates with incident AVF use by patients with ESRD but not with subsequent im

177 ex US for vascular mapping before upper limb AVF creation in participants with CKD.

178 s of temporary catheters and the overall low AVF maturation rate explain why a universal policy of AV

179 However, many AVFs fail before starting dialysis.

180 ntervention after achieving AVF maturation), AVF abandonment, and frequency of interventions.

181 Mean AVF diameters of at least 0.40 cm were seen in 85% (389

182 embryonic venous determinant Eph-B4 mediates AVF maturation.

183 In a mouse AVF model, Akt1 regulates fistula wall thickness and dia

184 tructure interaction (FSI) study in a murine AVF model using three mouse strains: NOS3 overexpression

185 ependent patients on hemodialysis with a new AVF created between 2010 and 2016.

186 12 months, 21 revisional procedures, 53 new AVFs, and 50 temporary dialysis catheters were required.

187 Nonfunctional AVF occurred in 21 (13.0%) patients, and they had a sign

188 When compared to NOS3+/+ and NOS3-/-, AVFs in the OE mice had larger lumen area.

189 tcome Measure: Epidemiologic, clinical, OCT, AVF, angiographic, and electrophysiological data at base

190 d controlled trial to evaluate the effect of AVF ligation on cardiac structure and function in stable

191 Although the likelihood of AVF abandonment was not higher among patients with up to

192 proach taking into account the likelihood of AVF maturation.

193 US measurements of AVF at 2-4 months in patients undergoing hemodialysis ar

194 eoperative VFT to ultrasound measurements of AVF blood flow rate and venous diameter at 1 day, 2 week

195 he population, 14% lost 5 degrees or more of AVF.

196 eter may be an under-recognized predictor of AVF maturation.

197 Utilization rates of AVF, arteriovenous graft, and intravascular hemodialysis

198 dventitia of the outflow vein at the time of AVF creation in the MSC group.

199 ent of novel strategies for the treatment of AVF dysfunction.

200 Treatment of AVF mice with CIMP significantly abrogated the contracti

201 ysis with a functioning AVF or AVG; 46.8% of AVFs were created <90 days before dialysis initiation.

202 mia, activates Notch in endothelial cells of AVFs, leading to accelerated neointima formation and AVF

203 The concept of AVFs in osseous flaps may be feasible for revascularizat

204 ch intracellular domain compared with ECs of AVFs in pair-fed control mice.

205 , and Notch target genes increased in ECs of AVFs in uremic mice.

206 Endothelial cells (ECs) of AVFs in uremic mice or patients expressed mesenchymal ma

207 While the feasibility of AVFs in soft tissues has been reported there is no study

208 ical management, with an increased number of AVFs placed and an improved likelihood of selecting the

209 ifferences in the patterns of utilization of AVFs are unknown and deserve evaluation.

210 cular health and function, but its effect on AVF maturation has not been fully characterized.

211 ESRD program may mitigate poverty effects on AVF use.

212 al diameter and other hemodynamic factors on AVF maturation is needed.

213 erative ultrasound criteria used to optimize AVF maturation.

214 in surviving patients without thrombosis or AVF intervention prior to 6 weeks, at least 50% of their

215 ong surviving patients without thrombosis or AVF intervention prior to week 2, 70% with upper-arm AVF

216 e aim to assess the flap survival of osseous AVFs in a pig model.

217 s been reported there is no study on osseous AVFs.

218 Overall AVF extent was predicted by vision and cognitive measure

219 Overall AVF maturation associated with preoperative arterial dia

220 ctors associated with unassisted and overall AVF maturation.

221 Elective ligation of patent AVF in adults with stable kidney transplant function res

222 ts with at least one cerebral or spinal pial AVF were screened for genetic disease.

223 unassisted AVF maturation for postmaturation AVF outcomes, including functional primary patency loss

224 ficant relationships with both postoperative AVF blood flow rate and diameter.

225 functional properties predict postoperative AVF measurements, patients enrolled in the Hemodialysis

226 ore common in patients receiving predialysis AVF than in patients receiving AVG (46.0% versus 28.5%;

227 /= 70 years) with CKD undergoing predialysis AVF or arteriovenous graft (AVG) creation from 2004 to 2

228 In all, 67% of patients with predialysis AVF and 71% of patients with predialysis AVG creation in

229 ation, an algorithm was developed to predict AVF outcome based on imaging findings.

230 anced MR angiography independently predicted AVF success in models including (odds ratio, 6.5; 95% co

231 ociation between the number of prematuration AVF interventions and the likelihood of functional prima

232 contrast, substantial increases in prevalent AVF rates from 30.9 to 38.6% (P < 0.001) among treatment

233 thesia, regional anesthesia improves primary AVF patency at 3 months.

234 10 to June 2012 with a catheter and no prior AVF; all had an AVF created within 6 months of starting

235 We hypothesize that NOS3 promotes AVF maturation by regulating local vascular mechanics fo

236 potential therapeutic approach for promoting AVF maturation.

237 and freedom of restenosis for radiocephalic AVFs, compared with an optimal cutoff point of 1120 mL/m

238 -abdominal infections, and, al. though rare, AVF.

239 ilure, almost one half of patients receiving AVFs initiated dialysis with a catheter.

240 raperitoneal injections of rapamycin reduced AVF wall thickness with no change in diameter.

241 g liposomes was also associated with reduced AVF wall thickness and both M1- and M2-type macrophages;

242 remodeling suggesting that Eph-B4 regulates AVF venous adaptation through an Akt1-mediated mechanism

243 Symmetrically shaped AVFs were found in just 34% of participants.

244 ic artery-superior mesenteric vein (SMA-SMV) AVF in a pancreas-after-kidney (PAK) transplant recipien

245 ion impairment scale in children with spinal AVF.

246 to a universal health care model, we studied AVF use within these organizations.

247 achial arterial dilatation with a successful AVF maturation and assessed the role of peribrachial adi

248 -times higher rate of achieving a successful AVF than those without.

249 o novel clinical tools to predict successful AVF maturation.

250 ial dilatation than patients with successful AVF during early period after surgery (0.85 vs. 0.43 mm,

251 ving an asymmetric as opposed to a symmetric AVF shape profile.

252 performance was associated with a symmetric AVF shape.

253 ional versus local anesthesia on longer-term AVF patency, we performed an observer-blinded randomized

254 These results show that AVF maturation is associated with acquisition of dual ar

255 Previous research suggested that AVF abandonment and interventions to maintain patency af

256 These same authors promoted the theory that AVF formation was directly related to procurement techni

257 The AVF group had a higher median overall annual access-rela

258 The AVF placement rate increased from 32% (126 of 395 patien

259 The AVF was assessed using a divided-attention protocol with

260 purposes of this study were to describe the AVF in a large sample of older drivers and identify demo

261 llowed by a synthetic vascular access if the AVF did not mature compared to (2) placing a synthetic v

262 volumes, and NT-proBNP were also seen in the AVF closure group ( P<0.01).

263 participants completed the study: 27 in the AVF ligation group and 27 in the control group.

264 I, 15.0-29.1) was observed in LV mass in the AVF ligation group compared with a small increase of 1.2

265 aberrant vascular mechanics at and near the AVF anastomosis.

266 very little is known about the shape of the AVF and the factors that affect it.

267 The shape of the AVF was classified as either symmetric or one of two asy

268 nclusion criteria and were randomized to the AVF ligation (n=33) or control (n=31) group.

269 he legs, and the hand and leg closest to the AVF or AVG received a higher dose.

270 was defined as dialysis initiation using the AVF, with time between AVF placement and dialysis start

271 AVF1st was the dominant strategy when the AVF maturation rate was 69% or greater.

272 The AVFs were created by anastomosis of genicular artery wit

273 s maladaptive remodeling by ligation of this AVF is unknown.

274 C57BL/J6 mice, and CIMP was administered to AVF and sham mice by protein transfer into peritoneal ca

275 A more selective approach to AVF placement reduces frequency of vascular access proce

276 nd this measure is shown to be equivalent to AVF.

277 output/index, brachial flows (ipsilateral to AVF), and pulmonary artery velocity.

278 th stable graft function) were randomized to AVF ligation or no intervention.

279 VA and 11 VB ventral cord motor neurons, two AVF interneurons and in unidentified neurons of the retr

280 Unassisted AVF maturation associated with preoperative arterial dia

281 ss compared with patients who had unassisted AVF maturation, and the risk increased with the number o

282 red patients with assisted versus unassisted AVF maturation for postmaturation AVF outcomes, includin

283 ents and hemodynamic factors with unassisted AVF maturation (successful use for dialysis without prio

284 tions compared with patients with unassisted AVF maturation, it was significantly higher among those

285 Multivariable regression models used AVF success as the dependent variable and age, sex, and

286 study, 82.6% initiated HD via HC, 14.0% via AVF, and 3.4% via AVG.

287 One-day and 2-week AVF flow rates and diameters were used to predict 6-week

288 , greater NMD associated with greater 6-week AVF blood flow rate and AVF diameter (per absolute 10% d

289 associated with greater increases in 6-week AVF blood flow rate and AVF diameter (per absolute 10% d

290 positively associated with changes in 6-week AVF blood flow rate and diameter, suggesting that native

291 central venous catheters (CVC), but whether AVF are associated independently with better survival is

292 ognitive, and vision factors associated with AVF performance and shape.

293 Macrophages are associated with AVF wall thickening and M2-type macrophages may play a m

294 Symptoms associated with AVF were recorded: heart failure, neurological deficit/s

295 relative hazards (RH) of death compared with AVF were 1.5 (95% confidence interval, 1.0 to 2.2) for C

296 azards associated with CVC, as compared with AVF, were stronger in men (n = 334; RH = 2.0; P = 0.01)

297 tal of 200 patients initially diagnosed with AVF/AVG dysfunction were referred to the radiology depar

298 Those initiating HD with AVF had 23% lower mortality than those initiating with a

299 Patients initiating HD with AVF had 35% lower mortality than those with HC (adjusted

300 and 52% (CI, 0.29-0.74), respectively, with AVF as reference standard (13 studies).